RENEE GRAHAM: Open Payments
NPI 1891481149 · SWANTON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$804 in 33 payments from 17 companies in 2025. Trend: 2023 $98 · 2024 $707 · 2025 $804
Food & beverage: $629Education: $175
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 4 | $145 |
| Janssen Biotech, Inc. | 7 | $138 |
| AstraZeneca Pharmaceuticals LP | 4 | $106 |
| Gilead Sciences, Inc. | 2 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| E.R. Squibb & Sons, L.L.C. | 2 | $38 |
| Novartis Pharmaceuticals Corporation | 2 | $37 |
| Eisai Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $26 |
| Celgene Corporation | 1 | $23 |
Products named: Trodelvy, JAKAFI, CARVYKTI, FRUZAQLA, OPDIVO, LYNPARZA, RYBREVANT, Lenvima.
Industry payments across MD — which companies pay providers there.
